Embecta (NASDAQ:EMBC) Sets New 1-Year Low – Time to Sell?

Embecta Corp. (NASDAQ:EMBC) reached a new 52-week low on Friday . The company traded as low as $9.06 and last traded at $9.18, with a volume of 111157 shares changing hands. The stock had previously closed at $9.44.

Wall Street Analyst Weigh In

A number of brokerages have commented on EMBC. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a research note on Wednesday, January 21st. BTIG Research restated a “buy” rating and issued a $25.00 target price on shares of Embecta in a report on Friday, February 6th. Finally, Wall Street Zen downgraded shares of Embecta from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 7th. One research analyst has rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Embecta currently has a consensus rating of “Hold” and a consensus price target of $18.50.

Embecta Price Performance

The stock has a market capitalization of $549.56 million, a PE ratio of 3.92 and a beta of 1.10. The company has a 50 day moving average price of $11.14 and a 200-day moving average price of $12.79.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. The company had revenue of $261.20 million during the quarter, compared to analyst estimates of $258.07 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The firm’s revenue was down .3% on a year-over-year basis. During the same quarter last year, the firm posted $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, equities analysts anticipate that Embecta Corp. will post 2.85 earnings per share for the current year.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 17th. Investors of record on Friday, February 27th will be given a dividend of $0.15 per share. The ex-dividend date is Friday, February 27th. This represents a $0.60 annualized dividend and a dividend yield of 6.5%. Embecta’s payout ratio is currently 25.32%.

Institutional Trading of Embecta

Several institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. grew its holdings in shares of Embecta by 36.3% during the 2nd quarter. American Century Companies Inc. now owns 5,195,948 shares of the company’s stock worth $50,349,000 after acquiring an additional 1,382,537 shares during the period. River Road Asset Management LLC boosted its position in shares of Embecta by 5.3% during the fourth quarter. River Road Asset Management LLC now owns 3,416,401 shares of the company’s stock valued at $40,587,000 after purchasing an additional 171,194 shares in the last quarter. Yacktman Asset Management LP grew its stake in Embecta by 0.7% in the second quarter. Yacktman Asset Management LP now owns 2,373,386 shares of the company’s stock worth $22,998,000 after purchasing an additional 16,069 shares during the period. State Street Corp raised its holdings in Embecta by 1.4% in the fourth quarter. State Street Corp now owns 2,360,626 shares of the company’s stock worth $28,044,000 after purchasing an additional 31,796 shares in the last quarter. Finally, Jefferies Financial Group Inc. lifted its position in Embecta by 24.9% during the fourth quarter. Jefferies Financial Group Inc. now owns 2,354,971 shares of the company’s stock valued at $27,977,000 after buying an additional 470,096 shares during the period. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.